Cyclic peptides can target specific interactions between proteins inside of cells, something that’s quite challenging with drugs under normal circumstances. Unfortunately, these peptides typically can’t enter cells on their own. Without intervention, studying their functionality is difficult at best. Here is how one team screened hundreds of different cyclic peptide conditions with Hydropore in minutes.

Hydropore™ is a novel, non-viral delivery platform now available for Research Use Only (RUO). Hydropore™ offers researchers a reliable alternative to electroporartion, and can rapidly and efficiently introduce nucleic acids, proteins and gene-editing complexes into cells for a variety of applications.

The most problematic step in GMCT manufacturing is the intracellular delivery of nucleic acids via transfection or transduction for expression of the CAR by the T cell. Current methods require significant hands-on time during production and require extensive intra- and post-production safety testing to avoid infusion of replication competent viruses at the time of therapy administration.

Microfluidic vortex shedding (µVS) has been shown to enable the efficient delivery of constructs like mRNA, plasmid DNA and Cas9 RNPs (CRISPR) to primary human T cells. But, what is µVS? And, how does µVS enable intracellular delivery of constructs to primary cells like activated T cells?

In this blog post, we will explore the advantages and limitations of some of the most common classes of therapeutics:  small molecules, macromolecules, nanoparticles, and chimeric antigen receptor T-cells.

Different CAR immune cells have different advantages and unique challenges or limitations. However, the expansion of CARs to other cell types has already begun and shows promising results. Here, we discuss alternative CAR-cell types such as CAR Natural Killer (CAR-NK) cells due to their current standing as the most popular alternative CAR-based therapy along with CAR macrophages (CAR-MF).

Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take advantage of the most significant advancements in immunology and genetic engineering. We explore the top new cell contenders in the growing CAR-T field including chimeric antigen receptor natural killer cells (CAR-NK) and the several characteristics which make them appealing for cancer therapy.